These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2997 related articles for article (PubMed ID: 27068280)

  • 1. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Olsson B; Lautner R; Andreasson U; Öhrfelt A; Portelius E; Bjerke M; Hölttä M; Rosén C; Olsson C; Strobel G; Wu E; Dakin K; Petzold M; Blennow K; Zetterberg H
    Lancet Neurol; 2016 Jun; 15(7):673-684. PubMed ID: 27068280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Ritchie C; Smailagic N; Noel-Storr AH; Ukoumunne O; Ladds EC; Martin S
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD010803. PubMed ID: 28328043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
    Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
    Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core CSF Biomarker Profile in Cerebral Amyloid Angiopathy: Updated Meta-Analysis.
    Charidimou A; Boulouis G
    Neurology; 2024 Oct; 103(7):e209795. PubMed ID: 39270153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY; Pei Z; Lee KC; Lopez-Brignoni E; Nikolov B; Crowley CA; Marsman MR; Barbier R; Friedmann N; Burns LH
    J Prev Alzheimers Dis; 2020; 7(4):256-264. PubMed ID: 32920628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
    Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
    Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glial activation and inflammation along the Alzheimer's disease continuum.
    Nordengen K; Kirsebom BE; Henjum K; Selnes P; Gísladóttir B; Wettergreen M; Torsetnes SB; Grøntvedt GR; Waterloo KK; Aarsland D; Nilsson LNG; Fladby T
    J Neuroinflammation; 2019 Feb; 16(1):46. PubMed ID: 30791945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.
    Salvadó G; Larsson V; Cody KA; Cullen NC; Jonaitis EM; Stomrud E; Kollmorgen G; Wild N; Palmqvist S; Janelidze S; Mattsson-Carlgren N; Zetterberg H; Blennow K; Johnson SC; Ossenkoppele R; Hansson O
    Alzheimers Dement; 2023 Jul; 19(7):2943-2955. PubMed ID: 36648169
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
    Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
    Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal cerebrospinal fluid measurements show glial hypo- and hyperactivation in predementia Alzheimer's disease.
    Nordengen K; Kirsebom BE; Richter G; Pålhaugen L; Gísladóttir B; Siafarikas N; Nakling A; Rongve A; Bråthen G; Grøntvedt GR; Gonzalez F; Waterloo K; Sharma K; Karikari T; Vromen EM; Tijms BM; Visser PJ; Selnes P; Kramberger MG; Winblad B; Blennow K; Fladby T
    J Neuroinflammation; 2023 Dec; 20(1):298. PubMed ID: 38093257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Race modifies the relationship between cognition and Alzheimer's disease cerebrospinal fluid biomarkers.
    Howell JC; Watts KD; Parker MW; Wu J; Kollhoff A; Wingo TS; Dorbin CD; Qiu D; Hu WT
    Alzheimers Res Ther; 2017 Nov; 9(1):88. PubMed ID: 29096697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease related biomarkers in bipolar disorder - A longitudinal one-year case-control study.
    Knorr U; Simonsen AH; Jensen CS; Zetterberg H; Blennow K; Akhøj M; Forman J; Hasselbalch SG; Kessing LV
    J Affect Disord; 2022 Jan; 297():623-633. PubMed ID: 34728295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.
    Alves G; Brønnick K; Aarsland D; Blennow K; Zetterberg H; Ballard C; Kurz MW; Andreasson U; Tysnes OB; Larsen JP; Mulugeta E
    J Neurol Neurosurg Psychiatry; 2010 Oct; 81(10):1080-6. PubMed ID: 20547614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurodegeneration and Glial Activation Related CSF Biomarker as the Diagnosis of Alzheimer's Disease: A Systematic Review and an Updated Meta- analysis.
    Hao Y; Liu X; Zhu R
    Curr Alzheimer Res; 2022; 19(1):32-46. PubMed ID: 34879804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 150.